VivoSim Labs to Add Rat Liver Model to NAMkind Platform
New cross-species capability is designed to help pharma distinguish rat-specific liver toxicity from risks that may translate to humans SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) — VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, today announced plans to […]
We haven't written up this one. Financial Post has the full story — the link below goes straight to it.
